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Background and Aims. Dysregulation of Akt has been implicated in diseases such as cancer and diabetes, although little is
known about the role of Akt deﬁciency on cardiomyocyte contractile function. This study was designed to examine the eﬀect
of Akt2 knockout-induced cardiomyocyte contractile response and the eﬀect of dietary supplementation of short-chain fatty
acid propionate on Akt2 knockout-induced cardiac dysfunction, if any. Methods and Results. Adult male wild-type (WT) and
Akt2 knockout mice were treated with propionate (0.3g/kg, p.o.) or vehicle for 7 days. Oral glucose tolerance test (OGTT) was
performed. Cardiomyocyte contractile function and mitochondrial membrane potential were assessed. Expression of insulin-
signaling molecules Akt, PTEN, GSK3β, and eNOS receptors for short-chain fatty acids GPR41, and GPR43 as well as protein
phosphatase PP2AA, PP2AB, PP2C were evaluated using Western blot analysis. Our results revealed that Akt2 knockout led to
overt glucose intolerance, compromised cardiomyocyte contractile function (reduced peak shortening and maximal velocity of
shortening/relengthening as well as prolonged relengthening), loss of mitochondrial membrane potential, decreased GPR41 and
elevated GPR43 expression, all of which, with the exception of glucose intolerance and elevated GPR43 level, were signiﬁcantly
attenuated by propionate. Neither Akt2 knockout nor propionate aﬀected the expression of protein phosphatases, eNOS, pan, and
phosphorylated PTEN and GSK3β. Conclusions. Taken together, these data depicted that Akt2 knockout may elicit cardiomyocyte
contractileandmitochondrialdefectsandabeneﬁcialroleofpropionateorshort-chainfattyacidsagainstAkt2deﬁciency-induced
cardiac anomalies.
1.Introduction
Cardiovascular disease, in particular heart disease, is the
leading cause of morbidity and mortality in the USA and the
rest of the world. Many risk factors have been conﬁrmed for
cardiovascular diseases including diabetes mellitus, insulin
resistance, hypertension, and obesity [1–3]. Among these
devastating factors, insulin resistance is the most recent
attention due to the obesity pandemic [2, 4]. Although
a number of scenarios have been postulated including
dyslipidemia, inﬂammation, endoplasmic reticulum, and
oxidative stress for insulin resistance-induced cardiovascular
dysfunction [5–10], the precise mechanisms behind car-
diac dysfunction in insulin resistance are still elusive thus
making adequate clinical management somewhat ineﬀective.
Although diet and exercise exhibit beneﬁcial eﬀects in
retarding the progression of insulin resistance-associated
cardiac anomalies, although the lifestyle remedies fail to
eradicate the cardiac pathologies [11]. Therefore, recent
attention has been geared towards identifying possible novel
therapy to either increase insulin sensitivity or circumvent
insulin resistance-induced impairment in the heart.
Insulin-receptor signaling plays an essential role in the
regulation of myocardial oxidative phosphorylation and
myocardial contractile function [3, 12]. This is supported
by the fact that insulin-receptor knockout drastically damp-
ens the oxidative phosphorylation and exacerbates cardiac
dysfunction [13, 14]. Although insulin-receptor signaling is
highly complex, involving a cascade of signaling molecules,
the phosphatidylinositol 3-kinase (PI3K)-Akt pathway is2 Experimental Diabetes Research
deemed the main player governing the majority of metabolic
properties of insulin, and thus represents an important
component in the insulin-signaling network [15, 16]. Akt
is a serine/threonine kinase directly downstream of PI3K to
mediate the metabolic actions of insulin [15]. Dysregulation
of Akt has been documented in a number of diseases
including cardiovascular diseases, cancer, and metabolic
disorders [17–19]. As a matter of fact, the onset of insulin
resistance and diabetes is often linked to changes in Akt
phosphorylation. Akt2 knockout has been demonstrated
to trigger global insulin resistance [20]. Nonetheless, a
number of mechanisms independent or upstream of Akt
may also contribute to the onset and progression of insulin
resistance such as upregulation of TNF-α and protein-
tyrosine phosphatase 1B [21].
Recent evidence has suggested a role of dietary ﬁber
(nonstarch polysaccharides) and a resistant starch in the
protection against insulin resistance and overall metabolic
syndrome [22, 23]. Dietary ﬁber and resistance starch may
escape digestion in the upper gastrointestinal tract and
undergo anaerobic fermentation in the colon. This process
produces short-chain fatty acids (SCFAs), predominantly
acetate, propionate, and butyrate, as the major by-products.
SCFAs are known to possess signiﬁcant biological eﬀects
on colonic epithelium both in vivo and in vitro [24].
Experimental evidence indicated that propionate is capable
of stimulating insulin secretion. Supplementation of propi-
onateinbaboonswasfoundtolowerthepostprandialblood-
glucose responsiveness [25]. However, dietary supplementa-
tion with propionate also decreased fasting serum glucose
and maximal insulin increments during a subsequent oral
glucose tolerance test [25].
Given that cardiac dysfunction is a major complication
in insulin resistance and that Akt-signaling anomalies have
been implicated in cardiac dysfunction [17, 26, 27], this
studywasundertakentoexaminetheeﬀectofAkt2knockout
on cardiomyocyte dysfunction, if any, and the impact of
propionate treatment on Akt2 knockout-induced cardiomy-
ocyte responses. In an eﬀort to elucidate the mechanisms of
action involved in Akt2 knockout and propionate-induced
cardiomyocyte mechanical and mitochondrial responses,
crucial protein markers of insulin signaling such as Akt,
phosphatase and tensin homologue on chromosome 10
(PTEN), glycogen synthase kinase 3β (GSK3β), eNOS,
and protein phosphatase, which usually negatively regulates
insulin signaling [28], were examined in hearts from wild-
type (WT) and Akt2 knockout mice.
2.MaterialsandMethods
2.1. Experimental Animals and Propionate Treatment. The
experimental procedures described in this paper were
approved by the University of Wyoming Animal Use and
Care Committee (Laramie, Wyo, USA). In brief, 5-6-month-
old adult male Akt knockout and the age-/gender-matched
wild-type (WT) mice were used. Production of the Akt
knockout mice was described in detail previously [20]. All
mice were housed in a temperature-controlled room under
a 12hr/12hr-light/dark and allowed access to tap water ad
libitum in the School of Pharmacy Animal Facility. Akt
knockout and wild-type mice were randomly assigned to
receive either propionate (0.3g/kg, p.o.) or vehicle (saline)
for 7 days.
2.2. Oral Glucose Tolerance Test (OGTT). Oral glucose
tolerance test was performed at the beginning and the end
of the treatment-period following a 6-hr fasting period
described previously [27]. Brieﬂy, 2g/kg glucose was given
using gavage following which blood-glucose levels were
measured using a glucometer (Accu-CheckII, model 792;
Boehringer Mannheim Diagnostics, Indianapolis, Ind, USA)
immediately before the glucose challenge or at 0, 30, 60, and
120min thereafter.
2.3. Isolation of Murine Cardiomyocytes. Single cardiomy-
ocytes were enzymatically isolated as described [27]. Brieﬂy,
hearts were removed and perfused (37◦C) with oxygenated
(5% CO2 :95% O2) Krebs-Henseleit bicarbonate (KHB)
buﬀer containing (in mM) 118 NaCl, 4.7 KCl, 1.2 MgSO4,
1.2 KH2PO4,2 5N a H C O 3, 10HEPES, and 11.1 glucose.
Hearts were subsequently perfused with a Ca2+-free KHB-
buﬀer that contains Liberase Blendzyme (10mg/mL; Roche,
Indianapolis, Ind, USA) for 15min. After perfusion, left ven-
tricles were removed and minced to disperse the individual
ventricular myocytes in Ca2+-free KHB-buﬀer. Extracellular
Ca2+ was added incrementally to 1.25mM. Myocytes with
obvious sarcolemmal blebs or spontaneous contractions
were not used. Only rod-shaped myocytes with clear edges
were selected for the recording of mechanical properties or
intracellular Ca2+ transients.
2.4. Cell Shortening/Relengthening. Mechanical properties of
cardiomyocytes were assessed using an SoftEdge MyoCam
system (IonOptixCorp., Milton, Mass, USA) [27]. Myocytes
were placed in a chamber mounted on the stage of an
inverted microscope (Olympus IX-70) and superfused with
ab u ﬀer containing (in mM) 131 NaCl, 4 KCl, 1 CaCl2,
1M g C l 2, 10 glucose, and 10HEPES, at pH 7.4. The cells
were ﬁeld stimulated with a suprathreshold voltage and
at a frequency of 0.5Hz (3ms duration) with the use of
a pair of platinum wires placed on opposite sides of the
chamber connected to an FHC Inc. stimulator (Frederick
Haer & Co., Brunswick, Neb, USA). The soft-edge software
(IonOptix) was used to capture changes in cell length during
contraction.Cell shortening and relengthening wereassessed
including peak shortening (PS): peak contractility, time-
to-PS (TPS): contraction duration, time-to-90% relength-
ening (TR90): relaxation duration, and maximal velocities
of shortening/relengthening (±dL/dt): maximal pressure
development and decline.
2.5. Measurement of Mitochondrial Membrane Potential
(MMP). MurinecardiomyocytesweresuspendedinHEPES-
saline buﬀer, and mitochondrial membrane potential (ΔΨm)
was detected as described [29]. Brieﬂy, after incubation
with JC-1 (5μM) for 10min at 37◦C, cells were rinsed
twice by sedimentation using the HEPES saline buﬀerExperimental Diabetes Research 3
WT
WT-propionate
AKTKO
AKTKO-propionate
0
100
200
300
400
0 3 06 09 0 120
Time after glucose injection (min)
S
e
r
u
m
g
l
u
c
o
s
e
l
e
v
e
l
(
m
g
/
d
L
)
(a)
WT AKTKO
0
10000
20000
30000
∗
∗
WT-
propionate
AKTKO-
propionate
A
U
C
g
l
u
c
o
s
e
(
m
i
n
×
m
g
/
d
L
)
(b)
Figure 1: Oral glucose tolerance test (OGTT, 2g/kg body weight) in WT and Akt2 knockout (AKTKO) mice treated with or without pro-
pionate (0.3g/kg, p.o.) for 7 days. (a) OGTT curve; (b) Area underneath the curve plotted in panel A. Mean ± SEM, n = 7-8 mice per group,
and ∗P<0.05 versus WT group.
free of JC-1 before being examined under a confocal
laser-scanning microscope (Leica TCS SP2) at excitation
wavelength of 490nm. The emission of ﬂuorescence was
recorded at 530nm (monomer form of JC-1, green) and at
590nm (aggregate form of JC-1, red). Results in ﬂuorescence
intensity were expressed as 590-to-530-nm emission ratio.
2.6. Western Blot Analysis. Protein expressions of Akt,
PTEN, PP2AA, PP2AB, PP2C, GSK3β, eNOS, GPR41,
and GPR43 were examined by Western blot analysis. Left
ventricular tissues were homogenized and centrifuged at
70,000g for 20min at 4◦C. The supernatants were used for
immunoblotting. The extracted proteins were separated on
10–15% SDS-polyacrylamide gels and transferred to nitro-
cellulose membranes. After being blocked, the membrane
was incubated with anti-Akt (1:1,000), anti-phospho-Akt
(pAkt, 1:1,000), anti-PTEN (1:1,000), anti-phospho-PTEN
(pPTEN, 1:1,000), anti-PP2AA (1:1,000), anti-PP2AB
(1:1,000), anti-PP2C (1:1,000), anti-GSK3β (1:1,000),
anti-phospho-GSK3β (1:1,000), anti-eNOS (1:1,000), anti-
GPR41 (1:1,000), anti-GPR43 (1:1,000), and anti-β-actin
(loading control, 1:2,000) antibodies at 4◦C overnight. All
antibodies were obtained from Santa Cruz Biotechnology
(Santa Cruz, Calif, USA) or Cell Signaling Technology (Bev-
erly, Mass, USA). After incubation with the primary anti-
bodies, blots were incubated with horseradish peroxidase-
linked secondary antibodies (1:5,000) for 60min at room
temperature. Immunoreactive bands were detected using
the Super Signal West Dura Extended Duration Substrate
(Pierce, Milwaukee, Wis, USA). The intensity of bands was
measuredwithascanningdensitometer(ModelGS-800;Bio-
Rad) coupled with a Bio-Rad personal computer analysis
software [27].
2.7. Statistical Analysis. Data were mean ± SEM. Statistical
signiﬁcance (P < 0.05) for each variable was determined by a
one-way ANOVA (two-way for OGTT) followed by Tukey’s
post hoc test.
3. Results
3.1. Eﬀect of Propionate Treatment on Whole-Body Glucose
Tolerance. Oral-glucose tolerance was performed at the end
of the 7-day propionate treatment. Following the oral-
glucose challenge, serum-glucose levels in WT mice started
to decline after peaking at 30min and returned back to near
baseline levels at 120min. In contrast to the WT mice, Akt2
knockout mice displayed glucose intolerance as evidenced
by a higher area under the curve (AUC) although neither
basal- nor postchallenge glucose levels were signiﬁcantly
diﬀerent between WT and Akt2 knockout mice. Propionate
treatment failed to aﬀect basal blood glucose or glucose-
disposal rate following oral-glucose ingestion in either WT
orAkt2knockoutmice.AUCinAkt2knockoutmiceremains
signiﬁcantly greater compared to the WT group (Figure 1).
3.2. Eﬀect of Propionate Treatment on Mechanical and Mito-
chondrial Properties of Cardiomyocytes. Mechanical prop-
erties revealed that the resting cell length was similar
in cardiomyocytes from WT and Akt2 knockout mice
with or without propionate treatment. Cardiomyocytes
from Akt2 knockout mice displayed signiﬁcantly reduced
peak shortening and maximal velocity of shortening/
relengthening (±dL/dt), prolonged time-to-90% relength-
ening (TR90) associated with unchanged time-to-peak short-
ening (TPS) compared with those from the WT mice.
Interestingly, these mechanical changes were ablated in
Akt2 knockout mice receiving propionate while propionate
itself failed to aﬀect cardiomyocyte mechanical properties in
cardiomyocytes from WT mice (Figure 2) .I no r d e rt ob e t -
ter understand the mechanism(s) underneath propionate-
exerted beneﬁcial eﬀect against Akt2 knockout-induced
myocardial contractile defect, JC-1 ﬂuorescence was used to4 Experimental Diabetes Research
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Figure 2: Cardiomyocyte mechanical function in WT and Akt2 knockout (AKTKO) mice treated with or without propionate (0.3g/kg, i.p.)
for 7 days. (a) Resting cell length; (b) peak shortening (PS, normalized to resting cell length); (c) maximal velocity of shortening (+dL/dt);
(d) maximal velocity of relengthening (−dL/dt); (e) time-to-PS (TPS); (f) time-to-90% relengthening (TR90). Mean ± SEM, n = 103-104
cells per group, ∗P < 0.05 versus WT group, and #P < 0.05 versus AKTKO group.
measure MMP. Cardiomyocytes from Akt2 knockout mice
displayed signiﬁcantly decreased MMP at both 30min and
90min, the eﬀect of which was also reconciled by propionate
treatment. Propionate itself did not alter MMP levels in WT
mice (Figure 3).
3.3. Eﬀects of Propionate Treatment on Akt and PTEN Sig-
naling. Western blot analysis revealed an overtly reduced
expression of Akt in Akt2 knockout mice, validating the
knockout model. Phosphorylation of Akt was signiﬁcantly
reduced in Akt2 knockout mice (although the normalized
Akt phosphorylation was unchanged after normalizing to
pan Akt level). Propionate treatment failed to alter pan
or phosphorylated Akt levels in Akt2 knockout mice,
although it signiﬁcantly attenuated Akt activation (absolute
or normalized values) without aﬀecting pan Akt level in WT
mice. Neither Akt2 knockout nor propionate treatment, or
both, aﬀected the levels of pan and phosphorylated PTEN
(Figure 4).Experimental Diabetes Research 5
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Figure 3: Cardiomyocyte mitochondrial membrane potential (MMP) in WT and Akt2 knockout (AKTKO) mice treated with or without
propionate (0.3g/kg, i.p.) for 7 days. MMP was measured using JC-1 ﬂuorochrome (ratio of red to green ﬂuorescence). (a) MMP at 30min;
(b) MMP at 90min. Mean ± SEM, n = 6-7 isolations, ∗P < 0.05 versus WT group, and #P < 0.05 versus AKTKO group.
3.4. Eﬀects of Propionate on Protein Phosphatase Expression.
To explore if protein phosphatase plays a role in Akt knock-
out or propionate-induced cardiac responses, expression
of protein phosphatases PP2AA, PP2AB, and PP2C was
evaluated. The results shown in Figure 5 demonstrate that
neither Akt2 knockout nor propionate treatment, or both,
aﬀectedtheexpressionofPP2AA,PP2AB,andPP2Cwiththe
exception of downregulated PP2AA levels in response to the
combination of Akt2 knockout and propionate.
3.5. Eﬀects of Propionate on GSK3β, eNOS, GPR41, and
GPR43 Expression. A sd e p i c t e di nF i g u r e6,W e s t e r nb l o t
analysis further revealed that neither Akt2 knockout nor
propionate altered the expression of eNOS, pan and phos-
phorylated GSK3β (or the pGSK3β-toGSK3β ratio). Akt2
knockoutsigniﬁcantlydown-andupregulatedtheexpression
of GPR41 and GPR43, respectively. Although propionate
treatment itself did not aﬀect the expression of GPR41
and GPR43 in WT mice, it abolished the downregulated
GPR41 without aﬀecting the upregulated GPR43 under Akt2
deﬁciency.
4. Discussion
OurresultsrevealthatpropionateattenuatedAkt2knockout-
induced cardiac contractile and mitochondrial dysfunction.6 Experimental Diabetes Research
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Figure 4: Eﬀect of propionate treatment (0.3g/kg, i.p. for 7 days) on Akt knockout-induced change in pan and phosphorylated Akt and
PTEN. (a) Pan Akt; (b) pan PTEN; (c) phosphorylated Akt (pAkt); (d) phosphorylated PTEN (pPTEN); (e) pAkt-to-Akt ratio; (f) pPTEN-
to-PTEN ratio. Insets: representative gel blots depicting expression and phosphorylation of these proteins using speciﬁc antibodies. β-Actin
was used as the loading control. Mean ± SEM, n = 4-5 mice per group, and ∗P < 0.05 versus WT group.
Propionate signiﬁcantly improved cardiomyocyte contractile
dysfunction including reduced peak shortening, maximal
velocity of shortening/relengthening, and prolonged TR90
in Akt2 knockout mice. Furthermore, the Akt2 knockout-
triggered loss in MMP and reduced expression of GPR41
were ameliorated by propionate. Neither Akt2 knockout
nor propionate signiﬁcantly aﬀected the levels of protein
phosphatases, eNOS, both pan and phosphorylated forms
of PTEN and GSK3β. These data depicted that Akt2
knockout may elicit cardiomyocyte contractile and mito-
chondrial defects and a beneﬁcial role of propionate against
Akt2 deﬁciency-induced cardiac mechanical anomalies. OurExperimental Diabetes Research 7
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Figure 5: Eﬀect of propionate treatment (0.3g/kg, i.p. for 7 days) on Akt knockout-induced change in protein phosphatase levels. (a) Repre-
sentative gel blots depicting expression of PP2AA, PP2AB, PP2C, and β-actin (loading control) using speciﬁc antibodies; (b) PP2AA; (c)
PP2AB; (d) PP2C. Mean ± SEM, n = 4-5 per group, and ∗P < 0.05 versus WT group.
ﬁndings have revealed therapeutic potential of propionate
and other SCFAs in insulin resistance-associated cardiac
dysfunction.
Our data conﬁrmed that the Akt2 knockout model
may serve as an insulin resistance model. These ﬁndings
support the pivotal role of Akt in the regulation of glucose
metabolism and myocardial function [17–19]. Although
the baseline glucose levels from Akt2 knockout mice were
somewhat similar to those from the WT mice, the area
underneath OGTT curve was signiﬁcantly greater in the
Akt2 knockout mice. These data validated the presence
of insulin resistance in Akt2 knockout model, consistent
with the notion of insulin resistance in this murine model
[20]. Along the same line, cardiomyocytes from Akt2
knockout mice exhibited reduced peak shortening, maximal
velocity of shortening/relengthening (±dL/dt) as well as
prolonged relengthening duration (TR90) associated with
comparable resting cell length and duration of shortening
(TPS) compared WT group. These ﬁndings are somewhat
consistent with our earlier ﬁndings using a sucrose or
high fat diet-induced insulin resistance model [26, 27,
30]. More importantly, our data revealed that propionate
treatment for 7 days was eﬀective in reversing cardiomyocyte
mechanical myocardial dysfunction in Akt2 knockout mice.
These compromised cardiomyocyte mechanical parameters
are reconciled by propionate treatment.
A number of mechanisms may be speculated for Akt2
knockout-induced cardiomyocyte anomalies and propion-
ate-oﬀered cardioprotection. First, emerging evidence has
indicated a role of mitochondrial function in the patho-
genesis and management of cardiac dysfunction in insulin
resistance [3]. Using mice with cardiac-speciﬁc overexpres-
sion of the heavy metal scavenger metallothionein, we found
that reduction of cardiac oxidative stress by metallothionein
protects against high fat diet-induced cardiac contractile
dysfunction through protection against mitochondrial dam-
age [31]. Our current ﬁndings exhibited that treatment
with propionate is capable of alleviating Akt2 knockout-
induced loss of MMP. It is plausible to speculate that
propionate-elicited beneﬁcial eﬀects against Akt2 knockout-
induced cardiomyocyte functional defects may be mediated
via alleviation of mitochondrial anomalies. Mitochondria
play a central role in the control of energy metabolism,
cell survival, and myocardial function [3]. Among many8 Experimental Diabetes Research
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Figure 6: Eﬀect of propionate treatment (0.3g/kg, i.p. for 7 days) on Akt knockout-induced change in pan and phosphorylated GSK3β,
eNOS, GPR41, and PGR43 levels. (a) pGSK3β-to-GSK3β ratio; (b) eNOS expression; (c) GPR41 expression; (d) GPR43 expression. Insets:
representative gel blots depicting expression and/or phosphorylation of these proteins using speciﬁc antibodies. β-Actin was used as the
loading control. Mean ± SEM, n = 4-5 mice per group, ∗P < 0.05 versus WT group, and #P < 0.05 versus AKTKO group.
cell signaling cascades involved in the regulation of cardiac
structure and function, Akt is known to exert a wide
range of regulatory responses on mitochondrial biology
[32]. Emerging research continues to unveil novel mecha-
nisms governing the protective eﬀects of Akt signaling in
the context of cardiac mitochondria. For example, recent
ﬁndings have suggested pivotal roles of hexokinase and
Pim-1 kinase in the preservation of mitochondrial function
downstream of Akt [32]. Moreover, Akt is capable of
suppressing mitochondrial permeation pore opening, thus
protecting mitochondrial integrity via phosphorylation of
GSK-3β [33]. Second, our data revealed that propionate
reconciled Akt2 knockout-induced loss in the receptors for
short-chain fatty acids GPR41. This is somewhat consistent
with the recent report that SCFAs regulate sympathetic
nervous system thus to control body energy expenditure and
metabolic homeostasis via GPR41 [34]. On the contrary,
Akt2 knockout signiﬁcantly upregulated the level of another
receptor for SCFAs, namely, GPR43, the eﬀect of which
was unaﬀected by propionate. These ﬁndings suggested
a role of GPR41 but not GPR43 in propionate-oﬀered
beneﬁcial cardiac eﬀects. GPR41 and GPR43 are deemed as
orphan G-protein coupled receptors that vary in speciﬁcity
for individual SCFAs, intracellular signaling, and tissue
localization [35, 36]. GPR43 exhibits comparable agonist
activities for acetate, propionate, and butyrate, whereas
GPR41 displays remarkable discrepancies in the rank order
for receptor aﬃnity (propionate ≥ butyrate > acetate) [35,
36]. Our ﬁndings revealed that both receptors may play a
role in Akt2 knockout-induced cardiomyocyte contractile
dysfunction, although only GPR41 (with a much higher
aﬃnity for propionate) may be responsible for the beneﬁcialExperimental Diabetes Research 9
eﬀect elicited by propionate. Further study is warranted to
betterelucidatethemechanismofactionbehindGPR41-and
GPR43-elicited metabolic and functional regulation in the
heart. Our data failed to identify any changes in the levels of
protein phosphatases, eNOS, pan and phosphorylated forms
of PTEN and GSK3β in either Akt2 knockout or propionate
treatment group, thus not favoring a role of these signaling
molecules in our current experimental settings. The levels
of Akt were greatly diminished in Akt2 mice, validating the
murine model. However, the Akt phosphorylation (ratio
between pAkt and Akt) remains unchanged, possibly due
to the remaining Akt2 or Akt1 levels in these hearts. To
our surprise, propionate treatment itself overtly dampened
phosphorylation of Akt although the precise mechanism of
action involved is still elusive at this time. Together with
the notion that dietary ﬁber and SCFAs may be beneﬁcial
to insulin resistance and metabolic syndrome [22, 23], our
ﬁndings have unveiled promises of SCFAs in the treatment of
cardiac pathologies in insulin resistance and other metabolic
disturbances.
Epidemiological evidence has depicted the beneﬁcial
eﬀect of dietary ﬁber in the clinical management of obesity,
diabetes, cancer, and cardiovascular diseases [37]. In par-
ticular, dietary ﬁbers improve fecal bulking and satiety, vis-
cosity and SCFA production, and reduce glycemic response.
The mechanism of action most likely responsible for the
beneﬁcial role of SCFAs involves the interference with lipid
digestion, cholesterol, and bile acid absorption, or with lipid
transport and deposition [37]. Moreover, although glucose
may serve as the main metabolic fuel, SCFAs produced
by colonic bacterial fermentation of dietary ﬁber furnish
a signiﬁcant portion of daily energy requirement [34, 38].
Maintenanceofenergyhomeostasisiscriticalforlife,andthe
dysregulation of which results in metabolic disorders [34],
depicting an important role of SCFAs in the management
of metabolic diseases. Nonetheless, the nutritional impact of
SCFAs may be easily confounded by changes in the relative
glycemic index of the test diets, thus the results may not
truly reﬂect the sole impact of fermentation or changes in
SCFAs [37]. Further in-depth study is warranted to explore
the complex nutritional and physiological eﬀects of dietary
ﬁbers and SCFAs.
In conclusion, results from our current study oﬀers evi-
dence, for the ﬁrst time, that Akt2 knockout compromised
cardiomyocyte contractile and mitochondrial dysfunction,
the eﬀects of which may be alleviated by short-term treat-
ment of propionate. In light of the present dismal status for
successful management against insulin resistance-associated
cardiac anomalies, it is tempting to speculate that propionate
and SCFAs may be of some particular clinical value in the
treatment and prevention of cardiac diseases associated with
insulin resistance.
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